A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
At 52 weeks, evolocumab added to diet alone, to low-dose atorvastatin, or to high-dose atorvastatin with or without ezetimibe significantly reduced LDL cholesterol levels in pat...
Publications
View AllAffiliated Researchers
Institution Info
- Type
- facility
- Country
- US
- Publications
- 1
- Citations
- 697
External Links
Identifiers
- ROR
- https://ror.org/04mq3gn83